coronavirus vaccine.So when AstraZeneca, a frontrunner in Phase 3 of global trials, unexpectedly hit pause on its study due to a participant becoming ill, prospects for an early rollout dimmed.While it might be disappointing, experts say it’s far from uncommon.In fact, there’s some comfort to be found in the temporary hold, according to Craig Jenne, an associate professor in microbiology, immunology and infectious diseases at the University of Calgary.“This is proof that the safety checks in place are robust and non-negotiable,” he said. “They didn’t wait for 10 patients to pause the study… We’re not willing to compromise safety to get a vaccine faster.” Canada secures 2 new deals for possible COVID-19 vaccines AstraZeneca announced it.